HIV Pre-exposure Prophylaxis

Challenges of clinical trial design, degree of evidence and recommendations in the era of PrEP

9.00 Registration

9.30 – 9.45 Welcome address
Dr. Constance Delaugerre, Hôpital Saint-Louis & Sidaction, France

9.45 What we know, what we are learning, and what more we need to do
Mr. Mitchell Warren, AVAC, USA
Where are we now? A review of recent results, current trials and planned trials
Prof. Robert Grant, MD, Gladstone Institute of Virology and Immunology, USA
PrEP Update: From intentions to use (Understanding safety, efficacy, correlates of protection, surrogate markers and trends in sexual behaviour)

11h15 Recommendations’ production
Dr. Kevin O’Reilly, WHO, Switzerland
Moving from research to implementation: What we still need to know
Dr. Roger Tatoud, Imperial College, Great Britain
PrEP in the UK: From research to policy and back

12.45 Lunch

14.00 Ongoing researches: objectives, designs, levels of evidence and ethical issues
Mr. Georges Sideris, The Warning, France
Mr. Hugues Fischer, Act Up-Paris, France
Mr. Jean-Marie Le Gall, Aides, France
Community-based organizations points of view on ethical issues
Prof. Benoît Mâsse, University of Montreal, Canada
Evaluating interventions without placebo controls

16.00 Round table
Chair: Mr. Christophe Martet, Yagg, France
Mr. Antonio Alexandre, SNEG, France
Prof. Jean-François Delfraissy, MD, ANRS, France
Mr. Stephen Karon, Ipergay’s Community Advisory Board, France
Prof. Jean-Michel Molina, MD, Hôpital Saint-Louis, France
Prof. Willy Rozenbaum, MD, Hôpital Saint-Louis, France
Dr. Bruno Spire, Aides, France

17.30 Concluding remarks
Mr. Vincent Douris and Mrs. Veronica Noseda, Sidaction, France

January 29, 2013 – Mairie du 10e arrondissement
72, rue Fbg. Saint-Martin, 75010 Paris – Metro station Château d’Eau, Line 4